Table 2 Differences in PROMIS scores for PCSK9i and statins.

From: Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial

PROMIS 10

Total

PCSK9i

Statins

P value

GPH

 Baseline

43.83 ± 4.97

44.20 ± 4.97

43.46 ± 4.96

0.141

 Week 12

48.46 ± 6.91

49.87 ± 7.09

47.04 ± 6.43

< 0.001

 Difference(baseline to week 12)

 

5.65 ± 8.37

3.54 ± 8.07

< 0.001

 Week 48

52.35 ± 6.41

52.87 ± 6.20

51.83 ± 6.58

0.120

 Difference(baseline to week 48)

 

8.73 ± 7.91

8.30 ± 8.38

0.600

GMH

 

 Baseline

46.25 ± 6.15

46.51 ± 6.38

45.99 ± 5.90

0.401

 Week 12

50.64 ± 7.67

52.09 ± 7.75

49.18 ± 7.31

< 0.001

 Difference(baseline to week 12)

 

5.45 ± 9.61

3.14 ± 8.91

< 0.001

 Week 48

54.13 ± 8.12

54.77 ± 7.64

53.49 ± 8.54

0.105

 Difference(baseline to week 48)

 

8.37 ± 10.31

7.43 ± 11.11

0.593

Back to article page